Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P060011/S045

RayOne Galaxy; Model RAO605G, RayOne Galaxy Toric; Model RAO615X

Rayner Intraocular Lenses , Ltd. · Decision date Sep 24, 2026

FDA DECISIONP060011/S045

What did the FDA approve?

FDA records P060011/S045 as a supplement to PMA P060011, with the supplement type “Panel Track”. The recorded decision is approval, dated Sep 24, 2026.

FDA approval order statement

Approval for the RayOne Galaxy (RAO605G) and the RayOne Galaxy Toric (RAO615X). RayOne Galaxy (Model RAO605G) is intended for primary implantation in the capsular bag of the eye for the visual correction of aphakia, in adult patients in whom a cataractous lens has been removed.The IOL mitigates the effects of presbyopia by providing improved intermediate and near visual acuity while maintaining comparable distance visual acuity to a monofocal IOL.RayOne Galaxy is intended for implantation in patients with less than 1.00 diopter of pre-existing corneal astigmatism. The RayOne injection system is used to fold and assist in inserting the IOL into the eye.RayOne Galaxy Toric (Model RAO615X) is intended for primary implantation in the capsular bag of the eye for the visual correction of aphakia, in adult patients in whom a cataractous lens has been removed.The IOL mitigates the effects of presbyopia by providing improved intermediate and near visual acuity while maintaining comparable distance visual acuity to a monofocal IOL.In addition, RayOne Galaxy Toric is intended to provide reduction of residual refractive astigmatism in patients with corneal astigmatism greater than or equal to 1.03 diopter, up to 3.07 diopter. The RayOne injection system is used to fold and assist in inserting the IOL into the eye.
Regulatory pathway
PMA supplement
Supplement type
Panel Track
Clinical specialty
Ophthalmic
Decision date
Sep 24, 2026
FDA change category
Labeling Change - Indications/instructions/shelf life/tradename

FDA source record

Regulatory record facts

Identifier
P060011/S045
Regulatory pathway
PMA supplement
Product code
MFK
Decision code
APPR
Decision date
Sep 24, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Lens, multifocal intraocular.

Product code
MFK
FDA device class
3

For the original device and its historical approval scope, see PMA P060011. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P060011 · Original PMA

    C-FLEX MODEL 570C INTRAOCULAR LENS (IOL)

  2. P060011/S045 received

    Application receipt date recorded by FDA.

  3. P060011/S045 · FDA decision

    Panel Track

Timeline entries are records held by MedtechLedger for P060011. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P060011

Product / regulatory recordCompanyPathwayDecision dateSource
Rayner Intraocular Lenses , Ltd.PMA approvalMay 3, 2007FDA

Explore the linked device profile

Other records with product code MFK

Product / regulatory recordCompanyPathwayDecision dateSource
Lenstec, Inc.PMA supplementOct 23, 2026FDA
Bausch + Lomb, Inc.PMA supplementOct 23, 2026FDA
Johnson & Johnson Surgical Vision, Inc.PMA supplementOct 19, 2026FDA
Bausch + Lomb, Inc.PMA supplementOct 14, 2026FDA
Bausch + Lomb, Inc.PMA supplementSep 30, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Rayner Intraocular Lenses , Ltd.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
1-2 Sackville Trading Estate,, Sackville Rd., Hove, E. Sussex, BN3 7AN

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records